Filed with ASX · · 2 pages · English
Clarity Pharmaceuticals Ltd has requested a trading halt for its securities pending a significant announcement regarding a response from the United States Food and Drug Administration. The halt will remain in effect until the earlier of the announcement being made or the commencement of normal trading on a specified date. The company has confirmed that it is not aware of any reasons why the trading halt should not be granted.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/trading-halt-2119
Market Announcement 11 November 2026 Clarity Pharmaceuticals Ltd (ASX: CU6) – Trading Halt Trading in the securities of Clarity Pharmaceuticals Ltd (‘CU6’) will be halted at the request of CU6, pending the release of an announcement by CU6. Unless ASX decides otherwise, the securities will...
Clarity Pharmaceuticals Ltd. on 6ix
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals